Eli Lilly and Company (NYSE:LLY) is Centric Wealth Management’s 6th Largest Position

Centric Wealth Management reduced its stake in shares of Eli Lilly and Company (NYSE:LLY) by 1.3% during the 3rd quarter, Holdings Channel.com reports. The firm owned 13,556 shares of the company’s stock after selling 181 shares during the period. Eli Lilly and Company makes up approximately 3.1% of Centric Wealth Management’s portfolio, making the stock its 6th largest position. Centric Wealth Management’s holdings in Eli Lilly and Company were worth $12,010,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. CWS Financial Advisors LLC lifted its position in shares of Eli Lilly and Company by 7.3% during the 3rd quarter. CWS Financial Advisors LLC now owns 1,200 shares of the company’s stock valued at $1,063,000 after acquiring an additional 82 shares during the period. Carl P. Sherr & Co. LLC increased its stake in Eli Lilly and Company by 0.4% in the 3rd quarter. Carl P. Sherr & Co. LLC now owns 5,526 shares of the company’s stock valued at $4,896,000 after purchasing an additional 24 shares in the last quarter. Hantz Financial Services Inc. boosted its position in Eli Lilly and Company by 0.9% during the third quarter. Hantz Financial Services Inc. now owns 17,961 shares of the company’s stock worth $15,912,000 after purchasing an additional 155 shares in the last quarter. Northwest & Ethical Investments L.P. boosted its position in Eli Lilly and Company by 25.4% during the third quarter. Northwest & Ethical Investments L.P. now owns 35,277 shares of the company’s stock worth $31,253,000 after purchasing an additional 7,154 shares in the last quarter. Finally, Pin Oak Investment Advisors Inc. increased its position in shares of Eli Lilly and Company by 22.4% in the third quarter. Pin Oak Investment Advisors Inc. now owns 120 shares of the company’s stock valued at $106,000 after buying an additional 22 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research report on Friday, September 13th. Evercore ISI upgraded shares of Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Barclays cut their price objective on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a research report on Thursday, October 31st. Sanford C. Bernstein initiated coverage on Eli Lilly and Company in a report on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 target price on the stock. Finally, Deutsche Bank Aktiengesellschaft dropped their price target on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating for the company in a research report on Monday, November 4th. Four research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average target price of $1,007.94.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the business’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the transaction, the chief accounting officer now owns 5,480 shares in the company, valued at $4,402,522.40. The trade was a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Stock Down 0.1 %

Shares of LLY opened at $788.19 on Friday. The firm has a market cap of $748.24 billion, a PE ratio of 85.21, a price-to-earnings-growth ratio of 2.99 and a beta of 0.43. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The company’s fifty day moving average is $854.42 and its two-hundred day moving average is $869.27. Eli Lilly and Company has a fifty-two week low of $561.65 and a fifty-two week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). The firm had revenue of $11.44 billion for the quarter, compared to analysts’ expectations of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. Eli Lilly and Company’s revenue was up 20.4% on a year-over-year basis. During the same period last year, the firm posted $0.10 EPS. Analysts forecast that Eli Lilly and Company will post 13.2 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 0.66%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 56.22%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.